Category Archives: Adult Stem Cells


BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union – BioSpace

NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today a lease agreement with the Tel Aviv Sourasky Medical Center (Sourasky) in Tel Aviv, Israel, to produce NurOwn in three state-of-the-art cleanrooms. The new facility will significantly increase the Companys capacity to manufacture and ship its product into the European Union and the local Israeli market. The cleanroom facility is part of Souraskys Institute for Advanced Cellular Therapies.

"Sourasky Hospital is a leader in the advancement and manufacturing of cell and gene therapy products and is well-equipped to rapidly scale up and produce NurOwn," stated Prof. Ronni Gamzu, CEO of Tel Aviv Sourasky Medical Center. "We look forward to continuing our work with BrainStorm to bring NurOwn to ALS patients and help fulfill the clinical therapy demands for the Companys pipeline programs.

"Sourasky Hospital, known for introducing pioneering solutions into clinical practice and advancing patient care, has a first rate team with the proven experience to produce regenerative products in accordance to the highest standard of cGMP manufacturing," said Chaim Lebovits, CEO of BrainStorm. "This agreement will ensure that we can provide NurOwn to patients after regulatory approval, not only in Israel but we have secured capacity to rapidly scale up production as we advance our investigational treatment across the European Union. We are very pleased to be able to expand our ongoing collaboration with Sourasky Hospital, one of the worlds most innovative and respected medical centers."

About NurOwn NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com

Safe-Harbor Statement Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

See the rest here:
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union - BioSpace

Stem Cells Market 2020 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and…

Global Stem Cells Market 2020 Global Industry report covers the latest market statistics, industry growth driving factors, size, share, trends, as well as Forecast till 2026. The Global Industrial Stem Cells market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Get a Sample Copy of the Report https://www.marketreportsworld.com/enquiry/request-sample/15567294

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cells market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

To know How COVID-19 Pandemic Will Impact This Market/Industry Request a sample copy of the report https://www.marketreportsworld.com/enquiry/request-covid19/15567294

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Global Stem Cells market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the TOP PLAYERS including;

For the data information by region, company, type, and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Enquire Before Purchasing this Report https://www.marketreportsworld.com/enquiry/pre-order-enquiry/15567294

The Stem Cells Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included in this report with Porters five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Stem Cells Breakdown Data by Type:

Stem Cells Breakdown Data by Application:

Purchase this Report (Price USD 3900 for Single User License) https://www.marketreportsworld.com/purchase/15567294

Stem Cells Market by Regions:

Key questions answered in the report:

Highlights of the report which will influence the Stem Cells market:

Major Points from Table of Contents:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Stem Cells Market Size Growth Rate by Type (2015-2026)1.4.2 Major-Type1.4.3 Independent-Type1.4.4 Administrator-Type1.5 Market by Application1.5.1 Global Stem Cells Market Share by Application (2015-2026)1.5.2 Commercial1.5.3 Commonweal1.5.4 Other1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Stem Cells Market Size2.2 Stem Cells Growth Trends by Regions2.2.1 Stem Cells Market Size by Regions (2015-2026)2.2.2 Stem Cells Market Share by Regions (2015-2020)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities

3 Market Share by Key Players3.1 Stem Cells Market Size by Manufacturers3.1.1 Global Stem Cells Revenue by Manufacturers (2015-2020)3.1.2 Global Stem Cells Revenue Market Share by Manufacturers (2015-2020)3.1.3 Global Stem Cells Market Concentration Ratio (CR5 and HHI)3.2 Stem Cells Key Players Head office and Area Served3.3 Key Players Stem Cells Product/Solution/Service3.4 Date of Enter into Stem Cells Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application4.1 Global Stem Cells Market Size by Type (2015-2020)4.2 Global Stem Cells Market Size by Application (2015-2020)

(5, 6, 7, 8, 9, 10, 11) United States, Europe, China, Japan, Southeast Asia, India, Central & South AmericaStem Cells Market Size (2015-2020)Key PlayersStem Cells Market Size by TypeStem Cells Market Size by Application

12 International Players ProfilesCompany DetailsCompany Description and Business OverviewStem Cells IntroductionRevenue in Stem Cells Business (2015-2020)Recent Development

13 Market Forecast 2020-202613.1 Market Size Forecast by Regions13.2 United States13.3 Europe13.4 China13.5 Japan13.6 Southeast Asia13.7 India13.8 Central & South America13.9 Market Size Forecast by Product (2020-2026)13.10 Market Size Forecast by Application (2020-2026)

14 Analysts Viewpoints/Conclusions

15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.1.1 Research Programs/Design15.1.1.2 Market Size Estimation12.1.1.3 Market Breakdown and Data Triangulation15.1.2 Data Source15.1.2.1 Secondary Sources15.1.2.2 Primary Sources15.2 Disclaimer15.3 Author Details

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Market Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Phone: US +1408 520 9750 / UK +44 203 239 8187

Other Reports Here:

Anti-drone Market 2020-Global Industry Trends, Share, Growth Insight, Size, Competitive Analysis, Statistics, Regional, And Global Forecast To 2023

Light Cure Adhesive Market 2020 Industry Size by Global Major Companies Profile, Competitive Landscape and Key Regions 2025 | Market Reports World

Industrial Fastener Seal Market Size, Share 2020 Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2022

Industrial Motor Busbar Market 2020 Globally Market Size, Analysis, Share, Research, Business Growth and Forecast to 2024 | Market Reports World

Computational Fluid Dynamics (CFD) Market Size, Share 2020 Global Business Growth, Trend, Segmentation, Top Key Players Analysis Industry, Opportunities and Forecast to 2024

Polyamide Resins Market Size, Share 2020|Global Trends, Industry Share, Growth Drivers, Business Opportunities and Demand Forecast to 2023

Medical Marijuana Market Size, Share 2020-Global Industry Trends, Growth Insight, Competitive Analysis, Statistics, Regional, And Global Forecast To 2024

Womens Footwear Market Size, Share Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Revenue Market Forecast 2026

More:
Stem Cells Market 2020 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and...

Chinas scientists accused of playing God by creating monstrous cloned apes and primates with human organs – The Sun

CHINESE scientists have been accused of being real-life Dr Frankensteins who play God by cloning apes and editing the genes of babies.

Some of their work has been dubbed monstrous while other cutting edge research could lead to cures for Parkinson's and Alzheimer's.

4

It's important to note that the US and the UK are not immune from conducting tests on animals and in fact carry out THOUSANDS of experiments on primates every year.

However, China has become the capital of research on apes and monkeys believing that our closest relatives hold the key to understanding brain disorders that destroy lives.

Incredibly, the Institute of Neuroscience (ION) in Shanghai, cloned five infant monkeys last year from an adult macaque who had been genetically-edited.

The result was baby primates intentionally born with a mutation that disrupts their wake-sleep cycle.

By giving the monkeys new drugs to treat their pre-existing brain disorders, the scientists hope to develop treatments for illnesses such as Alzheimer's disease.

It's no wonder the ION has been dubbed the "Cern of primate neurobiology".

The Institute successfully cloned two macaque monkeys in 2018 - a world first giving the experts confidence to push ahead with further experiments.

4

Heaping praise on the research, the Chinese Academy of Sciences said: "The achievement heralds a new era in which China can produce batches of standardised monkey clones, which will serve as animal models in the research of the brain's cognitive functions, early diagnoses and interventions of diseases, as well as research and development of drugs.

While China allows genetic manipulation on animals it has banned the use of gene-editing on humans but that hasn't stopped some of its scientists "playing God" with unborn children.

Scientist He Jiankui, 35, rocked the scientific world when he revealed he had altered the embryos of twin girls in 2018.

In December last year, it was revealed that a third child born to a different mum had also been gene-edited.

The rogue expert said he used a tool called Crispr to disable a gene that allows the AIDS virus to enter cells in a bid to make the children immune from the disease.

But why have such experiments been dubbed monstrous by others within the scientific community?

Experts claim gene-editing in people could "divide humans into subspecies" and can cause mutations, genetic problems and even cancer.

Dr Kiran Musunuru, an expert in this area from the University of Pennsylvania, called the experiment unconscionable an experiment on human beings that is not morally or ethically defensible.

4

Professor Julian Savulescu, of the University of Oxford, said: If true, this experiment is monstrous.

The embryos were healthy. No known diseases. Gene editing itself is experimental and is still associated with off-target mutations, capable of causing genetic problems early and later in life, including the development of cancer.

There are many effective ways to prevent HIV in healthy individuals: for example, protected sex.

Last December, Mr Jiankui was jailed for three years after news of the third child's birth was revealed.

He was convicted of practising medicine without a licence and fined 330,000 by a court in Shenzhen, the Xinhua news agency reported.

One of the most controversial experiments to date was the creation of embryos that were part human and part primate.

Last year, Spaniard Juan Carlos Izpisa Belmonte led a team of Chinese researchers with the end goal of creating monkeys which have entirely human organs such as kidneys or livers.

The organs will then be used for human transplants.

Based in China, the team made the chimeras a single organism with cells from more than one genotype - by injecting human stem cells into a fresh monkey embryo.

Biologist Belmonte previously tried adding human cells to embryos of pigs but the disturbing experiment was not successful.

However, because primates are genetically related to humans, the chances of the new research being successful is much greater.

The scientists also use gene-editing technology to disable certain cell formations in the animals to give the human cells a better chance of thriving.

4

In the US and other western democracies, such research is banned however in China, experts are allowed to push the boundaries of scientific ethics.

Importantly, no Frankenstein monster has been born as a result of this research... not yet anyway.

Instead, the hybrid embryos are allowed to develop for around two weeks so their progress can be studied.

Mr Belmonte defended his work with the Chinese, saying: History shows us time and time again that, over time, our ethical and moral standards change and mutate, like our DNA, and what yesterday was ethically unacceptable, if this really represents an advance for the progress of humanity, today it is already an essential part of our lives."

Live Blog

COVID CRISISCoronavirus UK LIVE: Lockdown extended by three weeks as nation claps for NHS

ANIMAL CRISISPets being abandoned over false virus claims animals can pass bug to humans

LET THE SUN SHINE25C Bank Holiday heatwave looks set to tempt Brits out of lockdown

Comment

DAN WOOTTONThe war gave us great young leaders...perhaps the coronavirus crisis will too

Latest

OPEN-AND-CUT CASESalon owner jailed for reopening during pandemic ordered to be RELEASED

LOUD & PROUDMillions of Brits clap and cheer our NHS heroes fighting virus on frontline

A similar experiment involved two piglets who were born with monkey cells in December at the State Key Laboratory of Stem Cell and Reproductive Biology in Beijing.

The so-called 'pig-monkey chimeras' died a week later.

Away from China, one of the most sinister experiments took place at the University of Munich where two monkeys were given transplanted pig hearts.

The poor creatures died after six months in a study which was deemed a success.

See more here:
Chinas scientists accused of playing God by creating monstrous cloned apes and primates with human organs - The Sun

Roeland Nusse receives Canada’s Gairdner International Award | The Dish – Stanford University News

by Krista Conger on May 6, 2020 3:43 pm

ROELAND NUSSE, professor of developmental biology, has received Canadas Gairdner International Awardfor his work on understanding the role of the Wnt signaling pathway in normal development and in cancer.

The Wnt pathway is made up of proteins, including one called Wnt, that transmit signals from outside the cell to the inside to trigger biological functions including gene expression and cell division.

Roeland Nusse was honored with Canadas Gairdner International Award for his work on the Wnt signaling pathway, which plays an important role in normal development and in cancer. (Image credit: Norbert von der Groeben)

The award recognizes excellence in fundamental research that affects human health.

Recipients receive 100,000 Canadian dollars (about $72,000) to use as they wish; Nusse plans to donate his award toUNICEF to help provide protective equipment for health care workers caring for children amid the global COVID-19 pandemic. Nusse is the Reed-Hodgson Professor in Human Biology and the Virginia and Daniel K. Ludwig Professor in Cancer Research.

In 1982, Nusse collaborated withHarold Varmus, then a professor in microbiology and immunology at the University of California, San Francisco, to identify Wnt as a critical cancer-associated gene in a mouse model of breast cancer. Nusse went on to show that the analogous gene in fruit flies, Wingless, plays an important role in regulating normal development. The finding highlighted the connections between normal development and cancer.

More recently, Nusse has focused his research on understanding how Wnt signaling regulates the activity of tissue-specific adult stem cells in response to injury or disease. In 2016, Nusse was awarded a $3million Breakthrough Prizefor his work on Wnt signaling.

Read the full article on the Stanford Medicine website.

Originally posted here:
Roeland Nusse receives Canada's Gairdner International Award | The Dish - Stanford University News

Broad Foundation brings together stem cell scientists, engineers and physicians at University of Southern – Mirage News

The Broad Foundation brings together stem cell scientists, engineers and physicians at USC and beyond

Developing new stem cell therapies requires more than a solo biologist having a eureka moment alone in the lab. Real progress relies on collaborations between biologists, engineers and physicians. Thats why The Eli and Edythe Broad Foundation has continued its support of two strategic initiatives: innovation awards bringing together teams of engineers and scientists from USC and Caltech, and clinical research fellowships for physician-scientists.

Engineering new approaches: The Broad Innovation Awards

For the fifth consecutive year, the Broad Innovation Awards are providing critical funding to USC-affiliated faculty members pursuing multi-investigator research collaborations related to stem cells. For the first year, these collaborations are also drawing on the expertise of biomedical engineers from Caltech. Each award provides $200,000 of funding for a one-year project.

Were very excited to be joining our colleagues at USC in pioneering new approaches to advancing stem cell research, said Stephen L. Mayo, chair of the Division of Biology and Biological Engineering at Caltech. Were thankful to The Broad Foundation for supporting cross-town collaborations between scientists with different expertise but common goals.

With support from a Broad Innovation Award, Andy McMahon, the director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, is collaborating with Caltech biomedical engineer Long Cai to leverage a new technology for understanding chronic kidney disease. The technology, called seqFISH, provides information about genetic activity taking place in intact tissueenabling the study of the interactions between cells in their native environments.

Dr. Cais seqFISH technology will provide an unprecedented insight into the cellular interplay underlying chronic kidney disease caused by a maladaptive response to acute kidney injury, said McMahon, who is the W.M. Keck Provost and University Professor of Stem Cell Biology and Regenerative Medicine, and Biological Sciences, as well as the chair of the Department of Stem Cell Biology and Regenerative Medicine at USC. We aim to better understand this maladaptive responsewhich is more common in malesin order to find new targets for preventing the progression to chronic kidney disease.

A second Broad Innovation Award brings together USC Stem Cell scientist Rong Lu and Caltech synthetic biologist Michael Elowitz. Their team will study the spatial organization of blood-forming stem and progenitor cells, also called hematopoietic stem and progenitor cells (HSPCs), which reside in the bone marrow. By pinpointing the locations of specific HSPCs, the scientists may find clues to explain why certain HSPCs are so dominantreplenishing the majority of the bodys blood and immune cells after a disruption such as a bone marrow transplantation.

Spatial advantages may be the primary drivers of what we refer to as the clonal dominance of certain HSPCs, said Lu, a Richard N. Merkin Assistant Professor of Stem Cell Biology and Regenerative Medicine, Biomedical Engineering, Medicine, and Gerontology at USC. Understanding the spatial competition between HSPCs could help improve bone marrow transplantation and provide new insights into aging and the development of diseases such as leukemiawhich are associated with clonal dominance.

Elowitz added: Thanks to the Broad Innovation Award and this exciting collaboration with Rong Lu, we will be able to bring a new, synthetic biology approach to record cell histories and read them out in individual cells within their native spatial context, providing new insights into fundamental questions in blood stem cell development.

A third Broad Innovation Award brings together three collaborators at USC: Michael Bonaguidi, an assistant professor of stem cell biology and regenerative medicine, biomedical engineering, and gerontology; Robert Chow, a professor of physiology and neuroscience, and biomedical engineering; and Jonathan Russin, an assistant professor of neurological surgery and associate surgical director for the USC Neurorestoration Center. Their project focuses on finding new approaches to treating epilepsy by studying neural cells called astroglia. These cells perform a variety of key functions that support the health of neurons in the brain, and they may also play a role in modulating epileptic seizures.

Although adults dont tend to generate many new brain cells, humans do produce a limited number of new astroglia, said Bonaguidi. We will examine these newborn astroglia at the single-cell level to better understand their role in epileptic patients, and to lay the groundwork for identifying new treatments.

The doctors are in: The Broad Clinical Research Fellowships

The Broad Clinical Research Fellowships are also entering their fifth consecutive year. These fellowships support stem cell research by physician-scientists and residents who intend to practice medicine in California.

These fellowships provide a very special opportunity for our medical residents to engage deeply in laboratory research, as a complement to their extensive training in patient care, said Laura Mosqueda, Dean of the Keck School of Medicine of USC. This valuable research experience gives them a much more complete perspective on how to meet the challenges of finding the best possible treatments for their patients.

A USC resident physician in general surgery, Kemp Anderson will spend his fellowship studying necrotizing enterocolitis, a very serious intestinal infection that affects nearly 10 percent of premature infants. Specifically, he will explore how a molecule involved in cellular communication, called farnesoid X receptor, or FXR, might contribute to this disease.

If FXR plays a role in compromising intestinal barrier function in these premature infants, then altering the activity of FXR could potentially yield treatment modalities for necrotizing enterocolitis, avoiding the morbidity and mortality associated with surgical intervention, said Anderson, who is performing the research under the mentorship of Christopher Gayer and Mark Frey at Childrens Hospital Los Angeles (CHLA). Im deeply appreciative of the benefactors and the selection committee for awarding me the Broad Clinical Fellowship, as it is allowing me devoted time to focus on this important project, and to become a more well-rounded physician through this academic pursuit.

Brittany Rocque, a resident physician in general surgery, will use her fellowship to seek better ways to predict, detect and diagnose immune rejection in patients who have undergone liver transplantation. Nearly 60 percent of pediatric patients and at least 15 percent of adult patients reject their liver transplants, and this can currently only be confirmed through an invasive surgical biopsy. Rocque is utilizing the technology Imaging Mass Cytometry to identify and analyze the types of immune cells involved in rejection.

My project has the potential to provide a noninvasive option to assess rejection in transplanted patients, and to expand our understanding of immune rejection, said Rocque, who is being co-mentored by Juliet Emamaullee and Shahab Asgharzadeh at CHLA. Im greatly looking forward to applying my passion for transplantation surgery in the context of basic science, and enhancing my appreciation for the nuances of research, thanks to the Broad Clinical Research Fellowship.

A hematology-oncology fellow who will be transitioning to a junior faculty position at USC next year, Caitlin ONeill will study a condition known as clonal hematopoiesis or CH, a phenomenon common in the aging population. CH involves genetic mutations that cause the expansion of a particular population of blood cells without leukemia or related malignancies. CH increases risks for certain health conditions including heart disease.

During her Broad Clinical Research Fellowship, ONeill will look at one mutation seen in patients with CH: a mutation to the gene called Tet methylcytosine dioxygenase 2, or TET2. ONeill will explore if this mutation promotes blood clots, inflammation and heart disease.

The goal is to inform therapies to prevent heart disease and leukemic progression in aging patients with CH, said ONeill, who is working with co-mentors Casey OConnell and Rong Lu at USC. Im very happy to be working on this project, with support from the Broad Clinical Research Fellowship, during my transition to becoming a faculty member at USC.

Read the original:
Broad Foundation brings together stem cell scientists, engineers and physicians at University of Southern - Mirage News

Schizophrenia drug points to improved brain cancer radiation therapy – New Atlas

Promising new research from the University of California, Los Angeles (UCLA), suggests an old schizophrenia drug could significantly enhance the efficacy of radiation treatment for one of the deadliest forms of brain cancer.

The general treatment process for glioblastoma, the deadliest adult brain cancer, is surgery followed by radiation therapy alongside a drug called temozolomide. This current standard-of-care still results in a nearly 95-percent mortality rate and, although radiation therapy does generally extend median survival duration, it can result in a dispiriting catch-22 scenario.

Compared to surgery alone, radiation therapy for glioblastoma extends survival duration by up to six months. However, radiation can also trigger a process called phenotype conversion, making it more likely the cancer will ultimately reoccur.

Phenotype conversion occurs when radiation therapy triggers a transformation in non-tumor stem cells, turning them into glioma-initiating cells. The goal of the new research was to find a pharmacological way to stop radiation initiating this phenotype conversion.

The first step was screening 83,000 different compounds to find a molecule that could effectively cross the blood-brain barrier and inhibit radiation-induced phenotype conversion. An old anti-psychotic drug called trifluoperazine, developed in the 1950s to treat schizophrenia, arose as a promising candidate.

The next step was conducting expansive animal tests to see if the drug, combined with radiation therapy, extended general survival rates. The results were incredibly promising, with all drug-treated animals surviving past 200 days, compared to a 67-day survival rate in the animals treated only with radiation.

Many preclinical glioblastoma studies report fairly small increases in overall survival in mice, and that rarely translates into benefits for patients, explains Frank Pajonk, senior author on the new study. But here we see pretty drastic effects in improved overall survival, and I find that very encouraging. It gives us hope that this is all going to translate into a benefit for people.

These very significant animal results suggest a straightforward combination of these two treatments could dramatically increase survival rates for human patients with glioblastoma. As the drug is already FDA-approved for clinical use, the researchers suggest human trials could commence as soon as later this year.

While radiotherapy is one of the few treatments that prolong survival in glioblastoma patients, radiation alone does very little in treating the disease in our models because we are dealing with highly aggressive tumors, says Pajonk. The drug trifluoperazine by itself does not do much either, but we found when you combine them, they become highly efficient. Importantly, the drug does not sensitize cells to radiation but rather prevents the occurrence of resistant glioma stem cells.

It is unclear exactly how the drug prevents phenotype conversion in the face of radiation, but the researchers hypothesize it is due to the nature of its dopamine receptor antagonism. Trifluoperazine is not commonly used in clinical practice nowadays as newer dopamine receptor antagonists have taken its place in psychiatric treatments, due to better efficacy and lower negative side effects.

I think we can find a combination of treatments with radiation that is very tolerable to patients and can do well, says Leia Nghiemphu, principal investigator on the upcoming clinical trial. The next step is to see if we can stop this resistance to radiation in humans.

The new study was published in the journal PNAS.

Source: UCLA

Go here to see the original:
Schizophrenia drug points to improved brain cancer radiation therapy - New Atlas

Scientists finally explained one of the strangest coronavirus symptoms – BGR

One of the qualities of the novel coronavirus that makes it so dangerous is that it doesnt have many specific symptoms that are telltale signs of an infection. Instead, the most common symptoms include signs that present with other viral infections, including the flu. Fever, cough, and shortness of breath might make you think youve been infected, but it can be something else entirely. The sudden loss of taste or smell is the closest thing we have to a telltale COVID-19 symptom, but it doesnt present itself in all those infected.

Other symptoms that can appear in COVID-19 cases can include sore throat, headache, muscle pain, and chills, but these can also develop in other conditions. Then there are gastrointestinal symptoms, including diarrhea and vomiting. The CDC doesnt include them in the list of COVID-19 symptoms but does mention that children might experience them. These gastrointestinal symptoms are unusual for respiratory diseases, but researchers have finally explained why it happens.

Scientists from Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have been able to grow an artificial gut (an organoid) from adult stem cells. they then tried to infect it with the SARS-CoV-2 virus that causes the COVID-19 disease. The researchers discovered that the virus can bind to epithelial cells of the intestine by hooking up to the same ACE2 receptor that lets them enter the lungs. They published their findings in Science Magazine.

Once these cells are invaded, the virus can continue to replicate and increase in number just like it does in the lungs. Moreover, the whole thing starts generating an immune response when the body detects the pathogen. These organoids contain the cells of the human intestinal lining, making them a compelling model to investigate infection by SARS-CoV-2, Hubrecht Institutes Hans Clevers told SciTech Daily.

Gastrointestinal symptoms can appear in up to one-third of COVID-19 patients, the report notes. There are worries that the virus can spread via fecal-oral transmission. Also, other studies theorized that fecal aerosols in bathrooms could infect other people.

Using electron microscopy, the scientists were able to determine the presence of the virus on gastrointestinal cells and found them replicating over time. The white regions in the image above indicate the presence of the coronavirus inside the cells of the organoid, which is colored in blue and green.

The researchers discovered that the virus can enter cells regardless of the level of ACE2 receptors. Even cells with low levels of ACE2 may become the host of replication for the virus. The researchers also looked at the response of the intestinal cells with RNA sequencing. They found that interferon-stimulated genes are activated after an infection, or genes that are known to fight a viral infection.

The observations made in this study provide definite proof that SARS-CoV-2 can multiply in cells of the gastrointestinal tract, Erasmus MCs Bart Haagmans told the blog. However, we dont yet know whether SARS-CoV-2, present in the intestines of COVID-19 patients, plays a significant role in transmission. Our findings indicate that we should look into this possibility more closely.

While the new study is definitely interesting, its unclear what sort of viral concentration in food is required to lead to diarrhea and nausea. Also, its unclear how infectious patients showing such symptoms are for other people. Not to mention that the research cant explain how fast the immune system would clear the gut. But the study proves yet again that good hygiene is of utmost importance whether theres an epidemic around or not.

On a related note, weve discussed before that ordering food from restaurants is safe even if said food is covered with the novel coronavirus. Thats because COVID-19 is a viral disease, and serious complications can arise only after the lungs are infected. Moreover, the actual cooking of food will also destroy all traces of the virus, which is why you should reheat your food at home if you want to be extra safe.

Image Source: Seth Wenig/AP/Shutterstock

Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. Whenever he's not writing about gadgets he miserably fails to stay away from them, although he desperately tries. But that's not necessarily a bad thing.

Go here to read the rest:
Scientists finally explained one of the strangest coronavirus symptoms - BGR

What Do New Neurons in the Brains of Adults Actually Do? – The Scientist

In the spring of 2019, neuroscientist Heather Cameron set up a simple experiment. She and her colleagues put an adult rat in the middle of a plastic box with a water bottle at one end. They waited until the rat started drinking and then made a startling noise to see how the animal would respond. The team did this repeatedly with regular rats and with animals that were genetically altered so that they couldnt make new neurons in their hippocampuses, a brain region involved in learning and memory. When the animals heard the noise, those that could make new hippocampal neurons immediately stopped slurping water and looked around, but the animals lacking hippocampal neurogenesis kept drinking. When the team ran the experiment without the water bottle, both sets of rats looked around right away to figure out where the sound was coming from. Rats that couldnt make new neurons seemed to have trouble shifting their attention from one task to another, the researchers concluded.

Aging humans, in whom neurogenesis is thought to decline, often have trouble remembering details that distinguish similar experiences.

Its a very surprising result, says Cameron, who works at the National Institute of Mental Health (NIMH) in Bethesda, Maryland. Researchers studying neurogenesis in the adult hippocampus typically conduct experiments in which animals have had extensive training in a task, such as in a water maze, or have experienced repetitive foot shocks, she explains. In her experiments, the rats were just drinking water. It seemed like there would be no reason that the hippocampus should have any role, she says. Yet in animals engineered to lack hippocampal neurogenesis, the effects are pretty big.

The study joins a growing body of work that challenges the decades-old notion that the primary role of new neurons within the adult hippocampus is in learning and memory. More recently, experiments have tied neurogenesis to forgetting, one possible way to ensure the brain doesnt become overloaded with information it doesnt need, and to anxiety, depression, stress, and, as Camerons work suggests, attention. Now, neuro-scientists are rethinking the role that new neurons, and the hippocampus as a whole, play in the brain.

Most of the research into neurogenesis involves boosting or inhibiting animals generation of new neurons, then training animals on a complex memory task such as finding a treat in a maze, and later retesting the animals. Decreasing neurogenesis tends to hamper the animals ability to remember.

Alzheimers disease, Parkinsons disease

Training mice or rats on a memory task before manipulating neurogenesis has also been found to affect the strength of the trained memory. Boosting neurogenesis reduced the memorys strength, perhaps an extreme form of forgetting that at normal levels avoids the remembering of unnecessary details.

Alzheimers disease and other forms of dementia

Research has linked decreased neurogenesis with more anxious and depressive behaviors in mice. Stress can reduce neurogenesis, ultimately leading mice to be more anxious in future stressful situations.

PTSD, anxiety, depression

Research has linked decreased neurogenesis with trouble switching focus.

Autism

The first hint that adult animal brains may make new neurons appeared in the early 1960s, when MIT neurobiologist Joseph Altman used radioactive labeling to track the proliferation of nerve cells in adult rats brains.Other data published in the 1970s and 1980s supported the conclusion, and in the 1990s, Fred Rusty Gage and his colleagues at the Salk Institute in La Jolla, California, used an artificial nucleotide called bromodeoxyuridine (BrdU) to tag new neurons born in the brains of adult rats and humans. Around the same time, Elizabeth Gould of Princeton University and her collaborators showed that adult marmoset monkeys made new neurons in their hippocampuses, specifically in an area called the dentate gyrus. While some researchers questioned the strength of the evidence supporting the existence of adult neurogenesis, most of the field began to shift from studying whether adult animal brains make new neurons to what role those cells might play.

In 2011, Ren Hen at Columbia University and colleagues created a line of transgenic mice in which neurons generated by neuro-genesis survived longer than in wildtype mice. This boosted the overall numbers of new neurons in the animals brains. The team then tested the modified mices cognitive abilities. Boostingnumbers of newly born neurons didnt improve the mices performances in water mazes or avoidance tasks compared with control mice. But it did seem to help them distinguish between two events that were extremely similar. Mice with more new neurons didnt freeze as long as normal mice when put into a box that was similar to but not exactly the same as one in which theyd experienced a foot shock in earlier training runs.

These results dovetailed with others coming out at the time, particularly those showing that aging humans, in whom neurogenesis is thought to decline, often have trouble remembering details that distinguish similar experiences, what researchers call pattern separation. The line of thinking is that the memories that are most likely to be impacted by neurogenesis are memories that are really similar to each other, says Sarah Parylak, a staff scientist in Gages lab at the Salk Institute.

As insights into pattern separation emerged, scientists were beginning to track the integration of new rodent neurons into existing neural networks. This research showed that new neurons born in the dentate gyrus had to compete with mature neurons for connections to neurons in the entorhinal cortex (EC), a region of the brain with widespread neural networks that play roles in memory, navigation, and the perception of time. (See Memories of Time on page 32.) Based on detailed anatomical images, new dentate gyrus neurons in rodents appeared to tap into preexisting synapses between dentate gyrus neurons and EC neurons before creating their own links to EC neurons.

To continue exploring the relationship between old and new neurons, a group led by the Harvard Stem Cell Institutes Amar Sahay, who had worked with Hen on the teams 2011 study, wiped out synapses in the dentate gyruses of mice. The researchers overexpressed the cell deathinducing protein Krppel-like factor 9 in young adult, middle-aged, and old mice to destroy neuronal dendritic spines, tiny protrusions that link up to protrusions of other neurons, in the brain region. Those lost connections led to increased integration of newly made neurons, especially in the two older groups, which outperformed age-matched, untreated mice in pattern-separation tasks. Adult-born dentate gyrus neurons decrease the likelihood of reactivation of those old neurons, Sahay and colleagues concluded, preventing the memories from being confused.

Parylak compares this situation to going to the same restaurant after it has changed ownership. In her neighborhood in San Diego, theres one location where shes dined a few times when the restaurant was serving different cuisine. Its the same location, and the building retains many of the same features, so the experiences would be easy to mix up, she says, but she can tell them apart, possibly because of neurogenesiss role in pattern separation. This might even hold true for going to the same restaurant on different occasions, even if it served the same food.

Thats still speculative at this point. Researchers havent been able to watch neurogenesis in action in a living human brain, and its not at all clear if the same thing is going on there as in the mouse brains they have observed. While many scientists now agree that neurogenesis does occur in adult human brains, there is little consensus about what it actually does. In addition to the work supporting a role for new neurons in pattern separation, researchers have accumulated evidence that it may be more important for forgetting than it is for remembering.

In recent years, images and videos taken with state-of-the-art microscopy techniques have shown that new neurons in the dentate gyrus of the hippocampus go through a series of changes as they link up to existing networks in the brain.

A neural stem cell divides to generate a new neuron (green).

As the new neuron grows, it rotates from a horizontal to a vertical position and connects to an interneuron (yellow) in a space called the hilus that sits within the curve of the dentate gyrus. The young neuron also starts making connections with well-established dentate gyrus neurons (blue) as well as neurons in the hippocampus (red).

Once connections are formed, mature neurons send signals into the new neuron, and the cell starts firing off more of its own signals. At around four weeks of age, the adult-born neuron gets hyperexcited, sending electrical signals much more often than its well-established neuronal neighbors do.

As the new neuron connects with still more neurons, interneurons in the hilus start to send it signals to tamp down its activity.

It seems counterintuitive for neurogenesis to play a role in both remembering and forgetting, but work by Paul Frankland of the Hospital for Sick Children Research Institute in Toronto suggests it is possible. In 2014, his team showed that when mice made more new neurons than normal, they were more forgetful. He and his colleagues had mice run on wheels to boost levels of neurogenesis, then trained the animals on a learning task. As expected, they did better than control mice who hadnt exercised. (See How Exercise Reprograms the Brain, The Scientist, October 2018.) In other animals, the researchers boosted neurogenesis after the mice learned information thought to be stored, at least in the short term, in the hippocampus. When we did that, what we found was quite surprising, Frankland says. We found a big reduction in memory strength.

His team was puzzled by the result. Adding to the confusion, the researchers had observed a larger effect in memory impairment with mice that learned, then exercised, than they had seen in memory improvement when the mice ran first and then learned. As he dug into the literature, Frankland realized the effect was what other neuroscientists had called forgetting. He found many theoretical papers based on computational modeling that argued that as new neurons integrate into a circuit, the patterns of connections in the circuit change, and if information is stored in those patterns of connections, that information may be lost. (See Memory Munchers on page 21.)

The notion surprised other neuroscientists, mainly because up to that point theyd had two assumptions related to neurogenesis and forgetting. The first was that generating new neurons in a normal animal should be good for memory. The second was that forgetting was bad. The first assumption is still true, Frankland says, but the second is not. Many people think of forgetting as some sort of failure in our memory systems, he explains. Yet in healthy brains theres tons of forgetting happening all of the time. And, in fact, its important for memory function, Frankland says. It would actually be disadvantageous to remember everything we do.

Experiments have tied neurogenesis to forgetting, anxiety, depression, stress, and attention.

Parylak says this idea of forgetting certainly has provoked a lot of discussion. Its unclear, for example, whether the mice in Franklands experiments are forgetting, or if they are identifying a repeat event as something novel. This is the point, she explains, where doing neurogenesis research in humans would be beneficial. You could ask a person if theyd actually forgotten or if they are making some kind of extreme discrimination.

Despite the questions regarding the results, Frankland and his colleagues continued their work, testing mices forgetfulness with all types of memories, and more recently they asked whether the forgetting effect jeopardized old and new memories alike. In experiments, his team gave mice a foot shock, then boosted hippocampal neurogenesis (with exercise or a genetic tweak to neural progenitor cells), and put the mice in the same container theyd been shocked in. With another group of mice, the researchers waited nearly a month after the foot shock before boosting neurogenesis and putting the mice back in the container. Boosting the number of new neurons, the team found, only weakened the newly made memory, but not one that had been around for a while. This makes a lot of sense, Frankland says. As our memories of everyday events gradually get consolidated, they become less and less dependent on the hippocampus, and more dependent on another brain region: the cortex. This suggests that remote memories are less sensitive to changes in hippocampal neurogenesis levels.

The hippocampus tracks whats happened to you, Frankland says. Much of thats forgotten because much of it is inconsequential. But every now and then something interesting seems to happen, and its these eventful memories that seem to get backed up in other areas of the brain.

Researchers think neurogenesis helps the brain distinguish between two very similar objects or events, a phenomenon called pattern separation. According to one hypothesis, new neurons excitability in response to novel objects diminishes the response of established neurons in the dentate gyrus to incoming stimuli, helping to create a separate circuit for the new, but similar, memory.

At NIMH, one of Camerons first studies looking at the effects of neurogenesis tested the relationship between new neuronal growth and stress. She uncovered the connection studying mice that couldnt make new neurons and recording how they behaved in an open environment with food at the center. Just like mice that could still make new neurons, the neuro-genesis-deficient mice were hesitant to go get the food in the open space, but eventually they did. However, when the animals that couldnt make new neurons were stressed before being put into the open space, they were extremely cautious and anxious, whereas normal mice didnt behave any differently when stressed.

Cameron realized that the generation of new neurons also plays a role in the brain separate from the learning and memory functions for which there was growing evidence. In her experiments, we were looking for memory effects and looked for quite a while without finding anything and then stumbled onto this stress effect, she says.

The cells in the hippocampus are densely packed with receptors for stress hormones. One type of hormone in particular, glucocorticoids, is thought to inhibit neurogenesis, and decreased neurogenesis has been associated with depression and anxiety behaviors in rodents. But there wasnt a direct link between the experience of stress and the development of these behaviors. So Cameron and her colleagues set up an experiment to test the connection.

When the team blocked neurogenesis in adult mice and then restrained the animals to moderately stress them, their elevated glucocorticoid levels were slow to recover compared with mice that had normal neurogenesis. The stressed mice that could not generate new neurons also acted oddly in behavioral tests: they avoided food when put in a new environment, became immobile and increasingly distressed when forced to swim, and drank less sugary water than normal mice when it was offered to them, suggesting they dont work as hard as normal mice to experience pleasure. Impaired adult neurogenesis, the experiments showed, played a direct role in developing symptoms of depression, Cameron says.

The notion that neurogenesis and stress might be tied directly to our mental states led Cameron to look back into the literature, where she found many suggestions that the hippocampus plays a role in emotion, in addition to learning and memory. Even Altman, who unexpectedly identified neurogenesis in adult rodents in the 1960s, and colleagues suggested as much in the 1970s. Yet the argument has only appeared sporadically in the literature since then. Stress is complicated, Cameron says; its hard to know exactly how stressful experiences affect neurogenesis or how the generation of new neurons will influence an animals response to stress. Some types of stress can decrease neurogenesis while others, such as certain forms of intermittent stress, can increase new neuronal growth. Last year, Cameron and colleagues found that generating new neurons helps rats used to model post-traumatic stress disorder recover from acute and prolonged periods of stress.

Neurogenesis appears to play a role in both remembering and forgetting.

Her work has also linked neurogenesis to other characteristics of rodent behavior, including attention and sociability. In 2016, with Gould at Princeton and a few other collaborators, she published work suggesting that new neurons are indeed tied to social behavior. The team created a hierarchy among rats, and then deconstructed those social ranks by removing the dominant male. When the researchers sacrificed the animals and counted new neurons in their brains, the rats from deconstructed hierarchies had fewer new neurons than those from control cages with stable ranks. Rats with uncertain hierarchies and fewer new neurons didnt show any signs of anxiety or reduced cognition, but they werent as inclined as control animals to spend time with new rats put into their quarters, preferring to stick with the animals they knew. When given a drugoxytocinto boost neurogenesis, they once again began exploring and spending time with new rats that entered their cages.

The study from Camerons lab on rats ability to shift their attention grew out of the researchers work on stress, in which they observed that rodents sometimes couldnt switch from one task to the next. Turning again to the literature, Cameron found a study from 1969 that seemed to suggest that neurogenesis might affect this task-switching behavior. Her team set up the water bottle experiments to see how well rats shifted attention. Inhibiting neurogenesis in the adult mice led to a 50 percent decrease in their ability to switch their focus from drinking to searching for the source of the sound.

This paper is very interesting, says J. Tiago Gonalves, a neuroscientist at Albert Einstein College of Medicine in New York who studies neurogenesis but was not involved in the study. It could explain the findings seen in some behavioral tasks and the incongruences between findings from different behavioral tasks, he writes in an email to The Scientist. Of course, follow-up work is needed, he adds.

Cameron argues that shifting attention may be yet another behavior in which the hippocampus plays an essential role but that researchers have been overlooking. And there may be an unexplored link between making new neurons and autism or other attention disorders, she says. Children with autism often have trouble shifting their attention from one image to the next in behavioral tests unless the original image is removed.

Its becoming clear, Cameron continues, that neurogenesis has many functions in the adult brain, some that are very distinct from learning and memory. In tasks requiring attention, though, there is a tie to memory, she notes. If youre not paying attention to things, you will not remember them.

Many, though not all, neuroscientists agree that theres ongoing neurogenesis in the hippocampus of most mammals, including humans. In rodents and many other animals, neurogenesis has also been observed in the olfactory bulbs. Whether newly generated neurons show up anywhere else in the brain is more controversial.

There had been hints of new neurons showing up in the striatum of primates in the early 2000s. In 2005,Heather Cameronof the National Institute of Mental Health and colleagues corroborated those findings, showing evidence of newly made neurons in therat neocortex, a region of the brain involved in spatial reasoning, language, movement, and cognition, and in the striatum, a region of the brain involved in planning movements and reacting to rewards, as well as self-control and flexible thinking (J Cell Biol, 168:41527). Nearly a decade later, using nuclear-bomb-test-derivedcarbon-14 isotopesto identify when nerve cells were born,Jonas Frisnof the Karolinska Institute in Stockholm and colleagues examined the brains of postmortem adult humans and confirmed thatnew neurons existed in the striatum(Cell, 156:107283, 2014).

Those results are great, Cameron says. They support her idea that there are different types of neurons being born in the brain throughout life. The problem is theyre very small cells, theyre very scattered, and therere very few of them. So theyre very tough to see and very tough to study.

See the article here:
What Do New Neurons in the Brains of Adults Actually Do? - The Scientist

Acute Myeloid Leukemia Therapeutics Market Latest Innovations, Drivers and Industry Key Events During Forecast 2017 2025 – Jewish Life News

Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection. Leukemia can grow along either the myeloid or lymphoid stem cell lines, it depends on the effect of genetic and epigenetic mutations on the progression of pluripotent stem cells to the various lines of mature cells which then pass into the blood. The effected line, combined with the rate of action and growth of disease reflects the four types of leukemias- Acute Myeloid Leukemia (AML), chronic lymphoblastic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia. AML: Acute Myeloid Leukemia, is a serious condition, its the most common leukemia suffered by adult people. According to a report from American Cancer Society, the average age for first diagnostic for AML is 64. With few days without treatment, AML develops fast, in duration of few weeks, the patient becomes severely ill. Due to its fast onset and acuteness in nature, there is no staging system for Acute Myeloid Leukemia (AML).The treatment for Acute Myeloid Leukemia (AML) has changed in last 4 decades.

Request to Sample report @ https://www.persistencemarketresearch.com/samples/16738

The drug approval process is difficult in AML, (many drugs have not been approved by USFDA, for instance Laromustine, Dacogen and Tipitarnib) efforts have been made to introduce new therapies in the AML market.

Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.

However, lack of targeted therapies in current acute myeloid leukemia (AML) therapeutics landscape, the drug difficult approval process in AML can hinder the growth of acute myeloid leukemia (AML) therapeutics market, but this restraint has opened an opportunity for key players to innovate acute myeloid leukemia (AML) therapeutics market.

How the Coronavirus Threat has Taken Global Business into Uncharted Waters

The global acute myeloid leukemia (AML) therapeutics market is segmented on the basic of disease subtype, treatment type, end user and region.

Based on the disease subtype, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:

Based on treatment type, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:

Based on end user, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:

The global acute myeloid leukemia (AML) therapeutics market is anticipated to show lucrative growth owing to increased investment in innovative technologies by key players. Players in this market using various strategies to fuel their global footprint and to gain a competitive edge. Product pipelines, new product launches, agreements and collaborations, acquisitions, mergers and clinical trials are some key strategies applied from global players in recent years are anticipated to give a robust hike to the market in the forecast period.

Geographically, acute myeloid leukemia (AML) therapeutics market is segmented into regions viz. North America, Latin America, Europe, Asia Pacific and Japan, Middle East and Africa. North America is anticipated to be major contributor to this market accounting maximum percent of share in AML therapeutics market followed by Europe. Slow but constant growth in prevalence for AML in North America is anticipated to fuel the growth in acute myeloid leukemia (AML) therapeutics market. In Asia pacific region, China and India are anticipated to show high growth in acute myeloid leukemia (AML) therapeutics market due to new developments in healthcare infrastructure in the region.

Request to View TOC @ https://www.persistencemarketresearch.com/toc/16738

The players in acute myeloid leukemia (AML) therapeutics market include,

For in-depth competitive analysis, buy [emailprotected] https://www.persistencemarketresearch.com/checkout/16738

Continued here:
Acute Myeloid Leukemia Therapeutics Market Latest Innovations, Drivers and Industry Key Events During Forecast 2017 2025 - Jewish Life News

Therapy Harnesses Immune System to Slow Progression of DIPG Brain Tumors – University of Michigan Health System News

Researchers are learning more about how to harness the immune system to find new treatment options for a deadly brain cancer that strikes young children.

Diffuse intrinsic pontine glioma, or DIPG, tumors cant be surgically removed due to their location on a critical structure of the brain called the brain stem. In addition, because of the presence of the blood-brain barrier, these tumors do not respond well to chemotherapy. Radiation is the most common treatment but its temporary, because the tumor grows back, and it isnt the ideal option for the young, developing brains of small children.

Some adult brain cancers, though, have responded to efforts to invigorate the immune system against the tumor, and a new study shows similar effects in animal models with one of the mutations that is present in human DIPG.

Immune-mediated gene therapy may lead us to a safe and effectivetherapeutic approach for DIPG in the future, says first author Flor Mendez, Ph.D.

MORE FROM MICHIGAN: Turning the Tables on Glioblastoma

The researchers treated mouse models with DIPG-like tumors in the brain stem, using an immunostimulatory gene therapy called TK/Flt3L to assess whether it would have a positive outcome on survival compared to regular care.

Together, these therapeutic genes sparked the immune system to recognize and kill the tumor cells, says Maria G. Castro, Ph.D., co-senior author.

We found anti-tumor immunity and an increase in anti-tumor specific T cells, says co-senior author Pedro Lowenstein, M.D., Ph.D. In this type of brain tumor, there are low numbers of immune cells in the tumor microenvironment, and this approach addresses that shortcoming.

Additionally the team found that the immune-mediated gene therapy was well tolerated and did not cause any adverse side effects. They say these results will pave the way for future clinical implementation of this immune-stimulatory gene therapy in DIPG patients at the University of Michigan and beyond.

The work was funded by the National Institutes of Healths National Institute of Neurological Disorders and Stroke, the ChadTough Foundation and the Leahs Happy Hearts Foundation.

Paper cited: Therapeutic efficacy of immune stimulatory thymidine kinase and fms-like tyrosine kinase 3 ligand (TK/Flt3L) gene therapy in a mouse model of high grade brainstem glioma, Clin Cancer Res. DOI: 10.1158/1078-0432.CCR-19-3714

MORE FROM MICHIGAN: Tackling Tumors That Always Come Back: New Brain Cancer Research Could Improve Outcomes

See the rest here:
Therapy Harnesses Immune System to Slow Progression of DIPG Brain Tumors - University of Michigan Health System News